AUTL News and Press, Autolus Therapeutics plc

The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated wi...

2024-05-17 13:52:53 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Autolus Therapeutics (NASDAQ: AUTL ) just reported results for the first quarter of 2024. Autolus Therapeutics reported earnings per share of -24 cents. This was below the...

2024-05-17 12:55:25 ET Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Conference Call May 17, 2024 8:30 AM ET Company Participants Olivia Manser – Investor Relations Christian Itin – Chief Executive Officer Rob Dolski – Chief Financial Offi...

2024-05-17 07:07:33 ET More on Autolus Therapeutics Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Call Transcript Autolus Therapeutics plc 2023 Q4 - Results - Earnings Call...

Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHA Two patients enrolled in Phase 1 Systemic Lupus Erythematosus (SLE) trial; study on track for initial data end of 2024 Market Authorization Application (M...

2024-05-14 13:02:31 ET Summary Autolus Therapeutics now has years of operational runway after recent financing. Operating expenses are manageable, with numerous pipeline projects in the hopper. Autolus likely has an approved therapy on their hands, just waiting for the Novembe...

LONDON, May 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of three abstracts submitted to the European Hematology Association (EHA...

2024-05-13 12:12:29 ET More on Autolus Therapeutics Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Call Transcript Autolus Therapeutics plc 2023 Q4 - Results - Earnings Call Presentation BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisitio...

LONDON, May 13, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it intends to file a Form 12b-25, Notification of Late Filing, with the U.S. Securities an...

2024-04-27 15:39:17 ET More on Amgen, Cullinan Oncology, etc. Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock Cullinan Therapeutics expands into autoim...